BeOne Medicines Ltd. (ONC) KPIs and segments
Close on Nov 18, 2026Market cap $45.89BP/E 72.2Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của BeOne Medicines · năm tài chính kết thúc Calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026)
Nhìn nhanh KPI của BeOne Medicines: 38 chỉ số vận hành, trong đó có Consolidated Total Revenue, BRUKINSA (zanubrutinib, BTKi) và TEVIMBRA (tislelizumab, Anti-PD-1), lấy từ 154 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Product revenue($M)4 | 1,680 | 1,487 | 1,476 | 1,395 | 1,302 | 1,109 | 1,118 | 993 | 921 | 747 | 631 | 595 | |
United States($M) | 899 | 766 | 850 | 743 | 685 | 563 | 616 | 504 | 479 | 351 | 313 | 270 | |
China($M) | 500 | 465 | 399 | 435 | 429 | 396 | 358 | 370 | 347 | 316 | 267 | 285 | |
Europe - total revenue($M) | 208 | 191 | 174 | 167 | 152 | 117 | 114 | 97.5 | 81.4 | 66.8 | 45.7 | 30.7 | |
Rest of world - total revenue($M) | 73.1 | 65.2 | 51.0 | 35.6 | 31.9 | 30.7 | 21.9 | 13.3 | 13.0 | 4.34 | 9.56 | ||
BRUKINSA($M) | 1,248 | 950 | |||||||||||
TEVIMBRA($M) | 229 | 194 | |||||||||||
XGEVA($M) | 104 | 81.3 | |||||||||||
Other($M) | 37.8 | 21.1 | 3.01 | ||||||||||
BLINCYTO($M) | 36.5 | 25.6 | |||||||||||
Other Revenue($M)4 | 25.3 | 26.1 | 17.3 | 13.2 | 8.75 | 9.79 | 8.15 | 8.02 | 4.73 | 3.88 | 186 | ||
United States($M) | 15.6 | 16.6 | 12.2 | 9.03 | 3.86 | 3.19 | 1.72 | 2.07 | 0 | 0 | 128 | ||
China($M) | 6.31 | 6.79 | 5.10 | 4.12 | 3.23 | 5.24 | 5.70 | 4.96 | 4.71 | 3.27 | 2.95 | ||
Rest of world - total revenue($M) | 3.03 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Europe - total revenue($M) | 0.35 | 2.68 | 0 | 0.07 | 1.66 | 1.37 | 0.74 | 1.00 | 0.02 | 3 | 54.9 | ||
KYPROLIS($M) | 15.1 | 19.4 | |||||||||||
POBEVCY($M) | 9.63 | 11.2 | |||||||||||
Kỳ báo cáo trước đây (báo cáo lần cuối 2023)4 | |||||||||||||
United States($M) | 914 | 782 | 864 | 755 | 694 | 567 | 619 | 505 | 481 | 351 | 313 | 398 | |
China($M) | 506 | 472 | 407 | 440 | 433 | 400 | 363 | 376 | 352 | 320 | 271 | 288 | |
Europe - total revenue($M) | 209 | 194 | 174 | 167 | 152 | 119 | 115 | 98.3 | 82.4 | 66.9 | 48.7 | 85.6 | |
Rest of world - total revenue($M) | 76.1 | 65.2 | 51.0 | 35.6 | 31.9 | 30.7 | 21.9 | 13.3 | 13.0 | 1.96 | 9.56 | ||
Consolidated Total Revenue ($M)($M) | 1,705 | 1,513 | 1,498 | 1,412 | 1,315 | 1,117 | 1,128 | 1,002 | 929 | 752 | 634 | 781 | |
BRUKINSA (zanubrutinib, BTKi) — Global Net Product Revenue ($M)($M)4 | 1,248 | 1,095 | 1,146 | 1,041 | 950 | 792 | 828 | 690 | 637 | 489 | 413 | 358 | |
BRUKINSA — Global Revenue Growth YoY (%)(%) | 31.4% | 38.3% | 50.8% | 49.0% | 62.1% | 93.0% | 106.8% | 131.1% | 130.0% | ||||
BRUKINSA — United States Net Product Revenue ($M)($M)1 | 893 | 761 | 845 | 739 | 684 | 563 | 616 | 504 | 479 | 352 | 313 | 270 | |
BRUKINSA — United States Revenue Growth YoY (%)(%) | 30.5% | 35.1% | 37.0% | 46.6% | 42.6% | 60.2% | 97.0% | 86.5% | 114.4% | 153.3% | 149.8% | ||
BRUKINSA — Europe Net Product Revenue ($M)($M)1 | 196 | 182 | 167 | 163 | 151 | 116 | 113 | 97.3 | 81.4 | 66.8 | 30.7 | ||
BRUKINSA — Europe Revenue Growth YoY (%)(%) | 30.0% | 57.4% | 67.8% | 84.9% | 73.4% | 217.2% | 209.2% | 242.8% | |||||
BRUKINSA — China Net Product Revenue ($M)($M)1 | 97.2 | 94 | 87.4 | 92.4 | 83.2 | 81.1 | 67.8 | 63.6 | 57.4 | 49.8 | 47.4 | ||
BRUKINSA — China Revenue Growth YoY (%)(%) | 16.7% | 15.9% | 36.2% | 30.8% | 41.3% | 43.0% | 31.2% | 19.4% | 20.8% | ||||
TEVIMBRA (tislelizumab, Anti-PD-1) — Global Net Product Revenue ($M)($M)1 | 229 | 206 | 182 | 191 | 194 | 171 | 154 | 163 | 158 | 145 | 128 | 144 | |
TEVIMBRA — Global Revenue Growth YoY (%)(%) | 18.1% | 20.5% | 18.0% | 16.7% | 22.2% | 17.8% | 20.0% | 12.8% | 5.9% | 26.4% | 12.6% | ||
Amgen In-Licensed Products — Total Net Product Revenue ($M)($M)4 | 157 | 142 | 112 | 133 | 126 | 114 | 102 | 90.1 | 71.9 | 50.4 | |||
Amgen In-Licensed Products — Revenue Growth YoY (%)(%) | 24.5% | 25.0% | 11.0% | 31.0% | 40.2% | 58.7% | 101.5% | 81.7% | |||||
XGEVA (denosumab, RANKL Inhibitor — Amgen In-Licensed) ($M)($M) | 105 | 89.9 | 70 | 84.2 | 81.3 | 70.4 | 62.5 | 63.5 | 55 | 43.4 | 24.2 | 24.5 | |
BLINCYTO (blinatumomab, CD19×CD3 BiTE — Amgen In-Licensed) ($M)($M) | 36.5 | 34 | 24.2 | 30.5 | 25.6 | 23.9 | 20.6 | 20.2 | 19.1 | 14.4 | 13.9 | 14.9 | |
KYPROLIS (carfilzomib, Proteasome Inhibitor — Amgen In-Licensed) ($M)($M) | 15.2 | 17 | 17.5 | 18.4 | 19.4 | 19.7 | 18.1 | 18 | 15.9 | 14.1 | 12.7 | 11.1 | |
POBEVCY (bevacizumab biosimilar — Bio-Thera In-Licensed) ($M)($M) | 9.60 | 12.1 | 11.9 | 10.5 | 11.2 | 13.7 | 13.1 | 12.2 | 11.6 | 16.6 | 14.7 | 14.1 | |
Other Marketed & Partnered Products — Net Product Revenue ($M)($M)2 | 37.8 | 33.2 | 24.5 | 20.1 | 21.1 | 17.9 | 21.8 | 26 | 23.6 | 24.6 | 84 | 13.7 | |
REVLIMID (lenalidomide — BMS/Celgene China Partnered) ($M, FY18–FY24)($M) | 3.60 | 11.1 | 9.10 | 12.2 | 16.1 | 15 | |||||||
VIDAZA (azacitidine — BMS/Celgene China Partnered) ($M, FY18–FY23)($M) | 2.50 | 4.30 | |||||||||||
Total Research & Development Expense ($M)($M)4 | 612 | 541 | 615 | 524 | 525 | 482 | 542 | 496 | 455 | 461 | 494 | 453 | |
Internal R&D Expense ($M)($M) | 365 | 354 | 361 | 320 | 315 | 291 | 315 | 325 | 296 | 289 | 281 | 296 | |
Total External R&D Expense ($M)($M)3 | 248 | 188 | 255 | 204 | 210 | 191 | 227 | 171 | 159 | 171 | 213 | 157 | |
External Cost of Development Programs ($M)($M) | 194 | 158 | 228 | 174 | 183 | 170 | 143 | 149 | 125 | 123 | 167 | 126 | |
Amgen Co-Development Expense Charged to R&D ($M)($M) | 30.3 | 29.4 | 26.9 | 30.1 | 26.4 | 20.7 | 22.2 | 17 | 22.5 | 13.5 | 13.7 | 16.3 | |
Upfront License & Development Milestone Fees ($M)($M)3 | 23.3 | 0.50 | 0 | 0.20 | 20.5 | 0 | 62.5 | 5 | 11.5 | 35 | 37.6 | 24.4 | |
Upfront License Payments Expensed to R&D ($M)($M) | 20 | 0.50 | 0 | 0.20 | 0.50 | 0 | 60 | 0 | 0 | 0 | 31.8 | 15 | |
Development Milestone Payments Expensed to R&D ($M)($M) | 3.30 | 0 | 35 | ||||||||||
Cash Payments for Acquired In-Process R&D ($M)($M) | 20.5 | 0 | 0 | 0.70 | 0 | 60 | 0 | 0 | 0 | 31.8 | 0 | 15 | |
Accrued External R&D Activities Liability ($M)($M) | 167 | 199 | 157 | 125 | 106 | 91.6 | 154 | 112 | 133 | 99 | 163 | 92.7 | |
Prepaid R&D Costs ($M)($M) | 48.2 | 36.1 | 52.6 | 70 | 76.2 | 44.1 | 64.3 | 60.2 | 68.2 | 66.8 | 60.5 | 73 | |
Amgen Collaboration — Total R&D Financing Commitment Expense ($M)($M)4 | 59.8 | 58 | 53.2 | 59.3 | 52.2 | 40.5 | 43.8 | 33.6 | 44.4 | 26.6 | 30.4 | 32.2 | |
Amgen R&D Financing Liability Amortization (Offset to R&D Expense) ($M)($M) | 29.5 | 28.6 | 26.2 | 29.3 | 25.8 | 19.8 | 21.6 | 16.6 | 21.9 | 13.1 | 16.7 | 15.9 | |
Amgen R&D Cost-Share Liability — Total Carrying Value ($M)($M)1 | 6.20 | 35.7 | 64.3 | 90.6 | 120 | 146 | 165 | 187 | 204 | 226 | 239 | 255 | |
Amgen R&D Cost-Share Liability — Current Portion ($M)($M) | 6.20 | 35.7 | 64.3 | 90.6 | 109 | 111 | 111 | 104 | 84.6 | 82 | 68 | 63.6 | |
Amgen Commercial Inventory Purchases (Related-Party) ($M)($M) | 132 | 124 | 43.6 | 84.2 | 73.3 | 62.7 | 94.7 | 43.1 | 47.6 | 62.2 | 50.7 | 18.8 | |
Amgen Remaining Co-Development Funding Commitment ($M)($M) | 12.5 | 72.3 | 130 | 184 | 243 | 295 | 335 | 379 | 413 | 457 | 484 | 518 | |
Profit-Share & Collaboration Reimbursement Expense — Total Net ($M)($M)3 | -15.6 | -15.4 | 17.6 | 15 | -17.1 | -17 | -82.8 | 11.6 | 11.9 | 10.3 | -88.8 | 11.1 | |
Reimbursement Expense — Cost of Sales ($M)($M) | 12.7 | 11.2 | -9 | -10 | 9.50 | 7.50 | -8.70 | -10.3 | -9.60 | -8.60 | -4 | -3.20 | |
Reimbursement Expense — Research & Development ($M)($M) | -1.10 | -0.20 | 0.60 | 0.40 | -1.60 | -0.50 | 1 | 0.30 | 0.40 | 0.70 | 0.10 | -0.40 | |
Reimbursement Expense — Selling, General & Administrative ($M)($M) | -27.1 | -26.4 | 25.9 | 24.6 | -25 | -23.9 | 22.8 | 21.6 | 21.1 | 18.1 | 16.9 | 14.7 | |
Gross Product Revenue Before Rebates & Returns ($M)($M)1 | 2,206 | 1,894 | 1,771 | 1,658 | 1,400 | 1,246 | 1,167 | 945 | 811 | 732 | |||
Sales Rebates, Returns & Discounts Deducted from Gross Revenue ($M)($M) | 526 | 406 | 376 | 356 | 292 | 252 | 246 | 198 | 180 | 136 | |||
Accrued Sales Rebates & Returns Reserve — Ending Balance ($M)($M)2 | 486 | 440 | 399 | 383 | 297 | 260 | 236 | 214 | 173 | 186 | 140 | 112 | |
Provision for Sales Rebates & Returns Charged to Revenue ($M)($M) | 526 | 406 | 426 | 376 | 356 | 292 | 312 | 252 | 246 | 198 | 180 | 136 | |
Payments & Credits Applied Against Sales Rebates & Returns Reserve ($M)($M) | 479 | 382 | 382 | 292 | 301 | 283 | 274 | 219 | 245 | 153 | 131 | 110 | |
Accrued Commercial Activities Liability ($M)($M) | 132 | 123 | 119 | 125 | 99.8 | 76.8 | 77.5 | 80.8 | 70.6 | 74.8 | 87.6 | 60.7 | |
GAAP Gross Margin (% of Global Product Sales)(%)3 | 90.0% | 89.0% | 90.4% | 85.9% | 87.4% | 85.1% | 85.6% | 83.0% | 85.0% | 83.0% | 83.2% | 83.8% | |
Non-GAAP Adjusted Gross Margin (% of Global Product Sales, FY23–FY25)(%) | 90.7% | 86.3% | 88.1% | 85.5% | 87.4% | 84.9% | 85.4% | 83.7% | 83.7% | ||||
GAAP Cost of Sales — Product ($M)($M) | 175 | 167 | 142 | 197 | 165 | 165 | 161 | 171 | 138 | 125 | 106 | 96.3 | |
Non-GAAP Adjusted Cost of Sales — Product ($M)($M) | 167 | 161 | 137 | 191 | 155 | 161 | 141 | 150 | 134 | 121 | 103 | 93.0 | |
Non-GAAP Adjusted Operating Expenses ($M)($M)3 | 1,035 | 938 | 1,016 | 880 | 886 | 817 | 908 | 786 | 746 | 778 | 799 | 705 | |
Non-GAAP Adjusted Research & Development Expense ($M)($M) | 534 | 466 | 545 | 446 | 444 | 421 | 475 | 406 | 383 | 405 | 437 | 396 | |
Non-GAAP Adjusted Selling, General & Administrative Expense ($M)($M) | 501 | 472 | 471 | 434 | 442 | 396 | 433 | 381 | 364 | 372 | 361 | 308 | |
GAAP SG&A Expense as % of Product Sales (%)(%) | 35.0% | 37.0% | 38.0% | 38.0% | 41.0% | 41.0% | 45.0% | 46.0% | 48.0% | 57.0% | 66.0% | 61.0% | |
Non-GAAP Adjusted Operating Income (Loss) ($M)($M)2 | 503 | 414 | 344 | 341 | 275 | 139 | 78.6 | 65.6 | 48.5 | -147 | -267 | -16.3 | |
Non-GAAP Adjusted Net Income (Loss) ($M)($M) | 444 | 375 | 225 | 304 | 253 | 136 | 16.1 | 51.6 | 23.3 | -146 | |||
Non-GAAP Free Cash Flow ($M)($M) | 435 | 161 | 380 | 354 | 220 | -12.3 | -17.3 | 54.7 | -206 | ||||
GAAP Diluted Earnings (Loss) per ADS ($/ADS, 1 ADS = 13 Ordinary Shares)($)7 | 2.05 | 1.96 | 1.09 | 0.84 | 0.01 | -1.15 | -1.15 | -2.41 | 2.01 | ||||
GAAP Basic Earnings (Loss) per ADS ($/ADS)($) | 2.12 | 2.05 | 1.13 | 0.87 | 0.01 | -1.15 | -1.15 | -2.41 | 2.06 | ||||
Non-GAAP Adjusted Diluted Earnings (Loss) per ADS ($/ADS)($) | 3.84 | 3.24 | 1.95 | 2.65 | 2.25 | 1.22 | 0.15 | 0.48 | 0.22 | -1.40 | |||
Non-GAAP Adjusted Basic Earnings (Loss) per ADS ($/ADS)($) | 3.98 | 3.38 | 2.03 | 2.76 | 2.33 | 1.27 | 0.15 | 0.49 | 0.22 | -1.40 | |||
Non-GAAP Adjusted Diluted Earnings (Loss) per Ordinary Share ($/sh)($) | 0.30 | 0.25 | 0.15 | 0.20 | 0.17 | 0.09 | 0.01 | 0.04 | 0.02 | -0.11 | |||
Non-GAAP Adjusted Basic Earnings (Loss) per Ordinary Share ($/sh)($) | 0.31 | 0.26 | 0.16 | 0.21 | 0.18 | 0.10 | 0.01 | 0.04 | 0.02 | -0.11 | |||
Weighted-Average Diluted ADSs Outstanding (M ADSs)(M) | 116 | 116 | 115 | 113 | 111 | 106 | 105 | 104 | 107 | ||||
Weighted-Average Basic ADSs Outstanding (M ADSs)(M) | 112 | 111 | 110 | 108 | 107 | 106 | 105 | 104 | 105 | ||||
Total Net Inventories ($M)($M)3 | 733 | 682 | 608 | 532 | 503 | 495 | 495 | 432 | 443 | 447 | 416 | 317 | |
Raw Materials Inventory ($M)($M) | 267 | 274 | 236 | 179 | 181 | 177 | 171 | 147 | 144 | 158 | 149 | 94 | |
Work in Process (WIP) Inventory ($M)($M) | 114 | 109 | 123 | 101 | 98.9 | 67 | 60.1 | 62 | 59.5 | 49.4 | 39.1 | 40 | |
Finished Goods Inventory ($M)($M) | 351 | 298 | 249 | 252 | 223 | 250 | 264 | 222 | 240 | 240 | 228 | 183 | |
Property, Plant & Equipment, Net ($M)($M)3 | 1,643 | 1,641 | 1,642 | 1,628 | 1,616 | 1,599 | 1,578 | 1,563 | 1,517 | 1,418 | 1,324 | 1,178 | |
Property, Plant & Equipment, Gross ($M)($M)6 | 2,110 | 2,077 | 2,043 | 1,985 | 1,715 | 1,437 | 1,324 | 1,304 | 942 | 900 | 833 | 768 | |
PP&E Gross — Buildings ($M)($M) | 1,205 | 1,197 | 1,188 | 1,168 | 933 | 704 | 608 | 608 | 305 | 281 | 232 | 215 | |
PP&E Gross — Manufacturing Equipment ($M)($M) | 289 | 283 | 274 | 267 | 259 | 252 | 244 | 249 | 227 | 217 | 187 | 173 | |
PP&E Gross — Laboratory Equipment ($M)($M) | 329 | 319 | 310 | 290 | 270 | 250 | 241 | 236 | 217 | 211 | 205 | 187 | |
PP&E Gross — Leasehold Improvements ($M)($M) | 79.5 | 77.2 | 76.6 | 73.8 | 74.5 | 63.1 | 64.7 | 60.7 | 60.4 | 59.4 | 60.1 | 53.1 | |
PP&E Gross — Software & Computer Equipment ($M)($M) | 136 | 130 | 124 | 115 | 107 | 102 | 100 | 83.8 | 67.7 | 66.7 | 83.3 | 74.8 | |
PP&E Gross — Land & Land Use Rights ($M)($M) | 71.4 | 71.4 | 71.4 | 71.4 | 71.4 | 65.5 | 65.5 | 65.5 | 65.5 | 65.5 | 65.5 | 65.5 | |
Accumulated Depreciation — PP&E ($M)($M) | 620 | 574 | 529 | 486 | 453 | 428 | 399 | 366 | 289 | 265 | 249 | 221 | |
Capital Expenditures Incurred but Not Yet Paid ($M)($M) | 5.90 | 43.2 | 5.20 | -5.90 | -2.10 | 60 | -5 | -40.2 | 15.1 | 101 | -15.8 | 12.2 | |
Finite-Lived Intangible Assets, Net ($M)($M)9 | 61 | 61.7 | 62.7 | 63.6 | 64.9 | 50.1 | 51.1 | 53.9 | 53.7 | 55.2 | 57.1 | 53.7 | |
Finite-Lived Intangible Assets, Gross ($M)($M)2 | 88.5 | 87.4 | 86.5 | 85.6 | 85.3 | 72.2 | 71.9 | 73.8 | 72.1 | 72.4 | 73.3 | 66.7 | |
Gross Intangibles — Developed Technology Rights ($M)($M) | 79.5 | 78.4 | 77.5 | 76.6 | 76.3 | 63.2 | 62.9 | 64.8 | 63.1 | 63.4 | 64.3 | 58.4 | |
Gross Intangibles — Licensing Agreements ($M)($M) | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 0.80 | |
Accumulated Amortization — Finite-Lived Intangible Assets ($M)($M)2 | 27.5 | 25.7 | 23.8 | 22 | 20.4 | 22 | 20.8 | 19.9 | 18.4 | 17.2 | 16.1 | 13.1 | |
Accumulated Amortization — Developed Technology Rights ($M)($M) | 19 | 17.2 | 15.3 | 13.6 | 11.9 | 13.6 | 12.4 | 11.5 | 10.1 | 8.90 | 7.80 | 6.60 | |
Accumulated Amortization — Licensing Agreements ($M)($M) | 8.50 | 8.50 | 8.50 | 8.50 | 8.40 | 8.40 | 8.40 | 8.40 | 8.30 | 8.30 | 8.30 | 0.80 | |
Net Intangibles — Developed Technology Rights ($M)($M) | 60.5 | 61.2 | 62.2 | 63 | 64.3 | 49.6 | 50.5 | 53.4 | 53 | 54.5 | 56.5 | 51.8 | |
Net Intangibles — Licensing Agreements ($M)($M) | 0.50 | 0.50 | 0.50 | 0.50 | 0.60 | 0.60 | 0.60 | 0.60 | 0.70 | 0.70 | 0.70 | 0 | |
Amortization of Intangible Assets — Total ($M)($M)2 | 1.60 | 1.80 | 1.60 | 1.60 | 5.80 | 1.20 | 1.20 | 1.30 | 1.20 | 1.20 | 3 | 2.30 | |
Amortization of Intangible Assets — Cost of Sales ($M)($M) | 1.60 | 1.70 | 1.50 | 1.50 | 5.80 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.10 | 1 | |
Amortization of Intangible Assets — Operating Expenses ($M)($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.10 | 0 | 0 | 1.80 | 1.30 | |
Estimated Intangible Amortization — Next 12 Months / Year 1 ($M)($M) | 6.50 | 8.10 | 6.30 | 8.30 | 6.20 | 4.80 | 4.80 | 4.90 | 4.80 | 4.80 | 5 | 6.20 | |
Estimated Intangible Amortization — Year 2 ($M)($M) | 6.50 | 8.10 | 6.30 | 8.30 | 6.20 | 4.80 | 4.80 | 4.90 | 4.80 | 4.80 | 5 | 6.20 | |
Estimated Intangible Amortization — Year 3 ($M)($M) | 6.50 | 8.10 | 6.30 | 8.30 | 6.20 | 4.80 | 4.80 | 4.90 | 4.80 | 4.80 | 5 | 6.20 | |
Estimated Intangible Amortization — Year 4 ($M)($M) | 6.50 | 8.10 | 6.30 | 8.30 | 6.20 | 4.80 | 4.80 | 4.90 | 4.80 | 4.80 | 4.80 | 6.20 | |
Operating Lease Right-of-Use (ROU) Assets ($M)($M)2 | 146 | 146 | 148 | 140 | 146 | 146 | 139 | 101 | 104 | 87.8 | 95.2 | 98.7 | |
Operating Lease Liabilities — Current ($M)($M) | 21.9 | 20.6 | 20.7 | 15.7 | 17.2 | 18.3 | 17.6 | 17.7 | 17.7 | 19.4 | 21.9 | 23.2 | |
Operating Lease Liabilities — Noncurrent ($M)($M) | 48.2 | 49.7 | 52.9 | 51.4 | 53.9 | 54.9 | 44.3 | 32.5 | 35.4 | 17.7 | 22.2 | 25.5 | |
Current Portion of Long-Term Debt & Bank Loans ($M)($M)2 | 191 | 116 | 57.3 | 808 | 764 | 852 | 864 | 852 | 827 | 688 | 329 | ||
Noncurrent Long-Term Debt & Bank Loans ($M)($M) | 882 | 963 | 962 | 146 | 160 | 167 | 188 | 185 | 199 | 198 | 203 | ||
Noncurrent Portion of RMB-Denominated Bank Loans (RMB M)(M) | 1,215 | 1,316 | 1,347 | 1,437 | 1,403 | 1,478 | |||||||
Unrecognized Tax Benefits (UTB) — Ending Balance ($M)($M)3 | 26.1 | 28.5 | 27.8 | 22 | 21.5 | 17.6 | 17.2 | 17.6 | 15.8 | 14.9 | 14.3 | 13.9 | |
Deferred Income Tax Liabilities, Net ($M)($M) | 57.4 | 55.9 | 53.2 | 47.1 | 44.1 | 43.1 | 42 | 15.9 | 15.9 | 16.4 | 16.5 | 16.4 | |
Income Taxes Paid, Net ($M)($M) | 70.6 | -2.70 | 20.7 | 2.90 | 67.7 | 9.30 | 14.7 | 9.10 | 43.1 | 2.50 | 13.5 | 10 | |
Noncurrent Value-Added Tax (VAT) Receivable ($M)($M) | 3.80 | 3.60 | 3.50 | 3.30 | 3.10 | 3.10 | 2.90 | 2.80 | 2.60 | 2.80 | 2.50 | 2 | |
Total Share-Based Compensation Expense ($M)($M)2 | 138 | 123 | 124 | 141 | 151 | 95.5 | 108 | 115 | 131 | 88.7 | 92.8 | 96.1 | |
Share-Based Compensation — Research & Development ($M)($M) | 58.5 | 53.9 | 52.4 | 58.8 | 64.4 | 41.8 | 45 | 47.7 | 55.4 | 38 | 39.4 | 44.1 | |
Share-Based Compensation — Selling, General & Administrative ($M)($M) | 78.9 | 69.5 | 71 | 82 | 86.2 | 53.7 | 62.8 | 66.9 | 75.3 | 50.7 | 53.3 | 52 | |
Global Full-Time Employees (Form 10-K / 10-Q & ESG Report) | 12,000 | 12,000 | 12,000 | 12,000 | 11,000 | 11,000 | 11,000 | 10,000 | 10,000 | 10,000 | |||
Income Statement — Total revenue ($M)($M)13 | 1,705 | 1,513 | 1,498 | 1,412 | 1,315 | 1,117 | 1,128 | 1,002 | 929 | 752 | 634 | 781 | |
Cost of sales — product ($M)($M) | 175 | 167 | 142 | 197 | 165 | 165 | 161 | 171 | 138 | 125 | 106 | 96.3 | |
Gross profit ($M)($M) | 1,531 | 1,346 | 1,356 | 1,216 | 1,151 | 952 | 967 | 831 | 791 | 627 | 529 | 685 | |
Research and development expense ($M)($M) | 612 | 541 | 615 | 524 | 525 | 482 | 542 | 496 | 455 | 461 | 494 | 453 | |
Selling, general and administrative expense ($M)($M) | 593 | 555 | 555 | 529 | 538 | 459 | 505 | 455 | 444 | 427 | 418 | 366 | |
Total operating expenses ($M)($M) | 1,206 | 1,096 | 1,171 | 1,053 | 1,063 | 941 | 1,047 | 951 | 898 | 888 | 912 | 819 | |
Income (loss) from operations ($M)($M) | 325 | 250 | 185 | 163 | 87.9 | 11.1 | -79.4 | -120 | -107 | -261 | -384 | -134 | |
Income (loss) before income taxes ($M)($M) | 313 | 259 | 149 | 147 | 99.5 | 20.9 | -85.4 | -98.3 | -106 | -243 | -351 | 229 | |
Income tax expense ($M)($M) | 75.5 | 31.9 | 82.7 | 22.3 | 5.20 | 19.6 | 66.5 | 23 | 14.5 | 7.70 | 16.8 | 13.9 | |
Net income (loss) ($M)($M) | 237 | 227 | 66.5 | 125 | 94.3 | 1.30 | -152 | -121 | -120 | -251 | -368 | 215 | |
Earnings (loss) per ordinary share — Basic ($/sh)($) | 0.16 | 0.16 | 0.09 | 0.07 | 0 | -0.09 | -0.09 | -0.19 | 0.16 | ||||
Earnings (loss) per ordinary share — Diluted ($/sh)($) | 0.16 | 0.15 | 0.08 | 0.06 | 0 | -0.09 | -0.09 | -0.19 | 0.15 | ||||
Weighted-average basic ordinary shares outstanding (M)(M) | 1,451 | 1,443 | 1,433 | 1,408 | 1,390 | 1,377 | 1,361 | 1,356 | 1,361 | ||||
Weighted-average diluted ordinary shares outstanding (M)(M) | 1,505 | 1,505 | 1,489 | 1,463 | 1,445 | 1,377 | 1,361 | 1,356 | 1,390 | ||||
Balance Sheet — Total assets ($M)($M)12 | 9,176 | 8,554 | 8,189 | 7,633 | 6,298 | 5,842 | 5,921 | 5,831 | 5,712 | 5,668 | 5,805 | 5,525 | |
Cash and cash equivalents ($M)($M) | 5,098 | 4,792 | 4,548 | 4,037 | 2,756 | 2,516 | 2,639 | 2,702 | 2,593 | 2,793 | 3,172 | 3,067 | |
Accounts receivable, net ($M)($M) | 1,056 | 938 | 865 | 863 | 771 | 717 | 676 | 569 | 529 | 435 | 358 | 309 | |
Inventories, net ($M)($M) | 733 | 682 | 608 | 532 | 503 | 495 | 495 | 432 | 443 | 447 | 416 | 317 | |
Total current assets ($M)($M) | 7,216 | 6,601 | 6,234 | 5,665 | 4,310 | 3,897 | 3,992 | 3,912 | 3,839 | 3,908 | 4,203 | 4,054 | |
Property, plant and equipment, net ($M)($M) | 1,643 | 1,641 | 1,642 | 1,628 | 1,616 | 1,599 | 1,578 | 1,563 | 1,517 | 1,418 | 1,324 | 1,178 | |
Intangible assets, net ($M)($M) | 61 | 61.7 | 62.7 | 63.6 | 64.9 | 50.1 | 51.1 | 53.9 | 53.7 | 55.2 | 57.1 | 53.7 | |
Accounts payable ($M)($M) | 470 | 424 | 479 | 384 | 361 | 365 | 405 | 308 | 333 | 357 | 315 | 342 | |
Total current liabilities ($M)($M) | 2,119 | 1,812 | 1,829 | 2,368 | 2,210 | 1,984 | 2,215 | 2,025 | 1,939 | 1,882 | 1,810 | 1,283 | |
Long-term bank loans ($M)($M) | 882 | 963 | 962 | 146 | 160 | 167 | 188 | 185 | 199 | 198 | 203 | ||
Total liabilities ($M)($M) | 4,002 | 3,793 | 3,827 | 3,503 | 2,528 | 2,342 | 2,589 | 2,395 | 2,346 | 2,307 | 2,268 | 1,762 | |
Accumulated deficit ($M)($M) | -7,856 | -8,093 | -8,320 | -8,386 | -8,511 | -8,606 | -8,607 | -8,455 | -8,334 | -8,213 | -7,962 | -7,595 | |
Total shareholders' equity ($M)($M) | 5,174 | 4,760 | 4,361 | 4,129 | 3,771 | 3,500 | 3,332 | 3,436 | 3,366 | 3,360 | 3,537 | 3,763 | |
Cash Flow Statement — Operating cash flow ($M)($M)4 | 463 | 201 | 417 | 403 | 264 | 44.1 | 75.2 | 188 | -95.6 | -309 | -222 | -78.1 | |
Capital expenditures ($M)($M) | 27.5 | 40.8 | 37.5 | 48.1 | 43.8 | 56.4 | 92.5 | 134 | 110 | 157 | 157 | 158 | |
Share-based compensation expense ($M)($M) | 138 | 123 | 124 | 141 | 151 | 95.5 | 108 | 115 | 131 | 88.7 | 92.9 | 96.1 | |
Investing cash flow ($M)($M) | -49.4 | -45.5 | -38.3 | -49.3 | -66.6 | -122 | -93.6 | -134 | -111 | -210 | -62.6 | -186 | |
Financing cash flow ($M)($M) | -6.10 | 68.6 | 96.9 | 961 | 35 | -33.8 | -4.50 | 12.7 | 23 | 162 | 347 | -76.8 | |
7 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Fiscal calendar & corporate identity: BeOne Medicines Ltd. (formerly BeiGene, Ltd.; redomiciled to Basel, Switzerland and renamed in May 2025; NASDAQ: ONC, HKEX: 06160, SSE STAR: 688235; 1 ADS = 13 ordinary shares) operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026; latest HKEX monthly return Sep 2026). BeOne operates as a single global oncology operating segment.
- Core commercial, STAR Market & R&D KPIs (Groups 1–6) cover: (1) Consolidated Revenue ($1,705.1M in Q2 2026 / $5,343.0M in FY25: Net Product Revenue $1,679.8M in Q2 2026 / $5,282.1M in FY25 and Collaboration/Other Revenue $25.3M in Q2 2026 / $61.0M in FY25) disaggregated across United States ($919.6M in Q2 2026 / $2,866.8M in FY25), China ($451.7M in Q2 2026 / $1,572.6M in FY25), Europe ($260.7M in Q2 2026 / $621.8M in FY25), and Rest of World ($73.1M in Q2 2026 / $281.8M in FY25); (2) Commercial Oncology Portfolio by medicine & region: BRUKINSA ($1,247.6M in Q2 2026 / $3,928.5M in FY25, +31.4% YoY in Q2 2026: U.S. $892.5M / +30.5%, Europe $206.4M / +37.3%, China $106.0M / +27.5%, RoW $42.7M / +30.6%), TEVIMBRA ($228.5M in Q2 2026 / $737.3M in FY25, +18.1% YoY in Q2 2026), Amgen in-licensed portfolio ($141.0M in Q2 2026 / $486.2M in FY25: XGEVA $104.5M, BLINCYTO $36.5M, KYPROLIS $17.8M in Q2 2026), POBEVCY ($14.6M in Q2 2026 / $62.0M in FY25), and legacy BMS/Celgene partnered brands; (3) SSE STAR Market (688235.SS) exclusive operational disclosures: physical production/purchase volume (6.27M vials in FY25), physical sales volume (6.00M vials in FY25), ending inventory (2.91M vials in FY25) of key self-developed/in-licensed products, and regional product gross margin split between Ex-China (94.75% in FY25) and Mainland China (70.11% in FY25); (4) R&D Expense ($562.1M in Q2 2026 / $2,145.9M in FY25) split into Internal R&D ($329.8M in Q2 2026 / $1,254.0M in FY25) and External R&D ($232.2M in Q2 2026 / $891.9M in FY25), 9-year molecule-level external R&D allocation from STAR Market reports (BRUKINSA, TEVIMBRA, Sonrotoclax/BEQALZI, BGB-16673/Tacabrutideg, BGB-43395), and Amgen/Novartis collaboration accounting; (5) Gross-to-Net (GTN) sales rebates deducted ($525.8M in Q2 2026) and Accrued Sales Rebates & Returns Reserve rollforward ($485.9M at Q2 2026); and (6) GAAP vs. Non-GAAP Gross Margin (90.0% GAAP in Q2 2026; 87.3% GAAP / 87.8% Adjusted in FY25), SG&A as % of product sales (35% in Q2 2026 vs. 80% in Q1 2023), Adjusted Operating Income ($517.8M in Q2 2026 / $1,100.0M in FY25), Adjusted Net Income ($446.1M in Q2 2026 / $917.6M in FY25), Non-GAAP Free Cash Flow ($429.9M in Q2 2026 / $941.7M in FY25), and GAAP/Adjusted EPS per ADS.
- Groups 7–11 cover: (7) 74 consecutive months of HKEX Form FF301 Monthly Returns (2020-08..2026-09): HKEX ordinary shares (1,427.23M at Sep 2026), SSE STAR RMB shares (115.06M at Sep 2026), 2016 Plan options outstanding (51.32M at Sep 2026), monthly grants/cancellations/exercises, BG NC 2, Ltd. award pool utilization (74.69M shares issued through Sep 2026), and monthly cash proceeds from option exercises ($7.99M in Sep 2026); (8) Manufacturing inventory by stage ($766.3M net at Q2 2026), PP&E by category ($1,613.5M net at Q2 2026), finite-lived intangibles & 5-year amortization schedule, and operating leases; (9) USD & RMB debt facilities, Unrecognized Tax Benefits rollforward ($65.4M at Q2 2026), Share-Based Compensation ($137.5M in Q2 2026), Issued U.S. (88) & China (77) patents at FY25, and DEF 14A CEO Pay Ratio (171:1 in FY25) & Pay vs. Performance; (10) Global Workforce (12,200 employees at Q2 2026 / 11,760 at FY25 across 5 regions; 2,520 new hires and 10.6% voluntary turnover in FY25), safety (0.14 TRIR / 0.08 LTIR in FY25), and Scope 1/2/3 GHG emissions, energy, water, and waste (FY19–FY25); and (11) FRED pharmaceutical benchmarks and DB financial statements.
- Swiss Standalone Statutory Financial Statements (prepared in CHF under the Swiss Code of Obligations for parent holding company BeOne Medicines Ltd., 2025) report CHF 490.2M in dividend income from subsidiaries and no external product revenue, and are in a different currency (CHF vs. USD) and accounting basis from U.S. GAAP consolidated statements; therefore no Consolidated − Standalone subtraction is performed. The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.
Dữ liệu cập nhật 2026-10-29.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Consolidated Revenue by Type & Geographic Region ($M)
Commercial Oncology Portfolio — Revenue by Medicine & Region ($M, YoY %)
- BRUKINSA (zanubrutinib, BTKi) — Global Net Product Revenue ($M) ($M)30 kỳ
- TEVIMBRA (tislelizumab, Anti-PD-1) — Global Net Product Revenue ($M) ($M)30 kỳ
- Amgen In-Licensed Products — Total Net Product Revenue ($M) ($M)11 kỳ
- POBEVCY (bevacizumab biosimilar — Bio-Thera In-Licensed) ($M) ($M)22 kỳ
- Other Marketed & Partnered Products — Net Product Revenue ($M) ($M)26 kỳ
SSE STAR Market (688235.SS) Physical Volume (Vials) & Regional Gross Margin Breakdown
R&D Expense by Pipeline Molecule, Internal vs. External R&D & Collaborations ($M)
Gross-to-Net (GTN) Sales Rebates & Returns Rollforward ($M)
GAAP vs. Non-GAAP Profitability, Gross Margin & Per-ADS Metrics
HKEX Monthly Returns (Form FF301, 06160.HK) — Issued Shares & Option Activity (2020-08..2026-09)
Manufacturing Inventory by Stage, PP&E Breakdown, Intangibles & Leases ($M)
Debt Facilities ($M / RMB M), Taxes & UTB, Share-Based Comp, Patents & Governance
- Current Portion of Long-Term Debt & Bank Loans ($M) ($M)35 kỳ
- Unrecognized Tax Benefits (UTB) — Ending Balance ($M) ($M)38 kỳ
- Total Share-Based Compensation Expense ($M) ($M)46 kỳ
- Issued U.S. Patents Held at Year-End (patents, Form 10-K Intellectual Property)8 kỳ
- CEO Pay Ratio (x:1, DEF 14A Proxy Statement) (×)6 kỳ
Global Workforce, Workplace Safety & Environmental Sustainability (10-K / ESG Reports)
Industry & Macro Healthcare Benchmarks (FRED) & Core Financial Statements (DB)
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của BeOne Medicines
See a number that looks wrong?